Clinical significance and management of prostatic intraepithelial neoplasia.
- Author:
Zifu CHEN
1
Author Information
1. Department of Urology, Fujian Provincial Hospital, Fuzhou, Fujian 350001, China. chenzifu32@163.com
- Publication Type:Journal Article
- MeSH:
Biopsy, Needle;
Humans;
Male;
Neoplasm Staging;
Prostate-Specific Antigen;
blood;
Prostatic Intraepithelial Neoplasia;
diagnosis;
pathology;
Prostatic Neoplasms;
diagnosis;
pathology
- From:
National Journal of Andrology
2004;10(12):883-885
- CountryChina
- Language:Chinese
-
Abstract:
Prostatic intraepithelial neoplasia (PIN) refers to the cellular proliferations within prostatic ducts, ductules, and acini. PIN is divided into three grades, PIN 1, PIN 2 and PIN 3, PIN 1 is a low grade (LPIN); PIN 2 and PIN 3 are high grades (HPIN). Clinically, the term PIN is usually used to indicate HPIN. LPIN is not used as a separate pathological diagnostic entity. HPIN is widely regarded as the precancerous change of prostatic carcinoma. HPIN and prostatic carcinoma share many similarities in epidemiology, genetics, morphology, as well as in location and clinical features. And so they are two closely related entities. HPIN is pathologically diagnosed, and shows no specificity on digital rectal examination (DRE) and transrectal ultrasonography (TRUS). HPIN does not elevate serum prostatic specific antigen (PSA) concentration. HPIN with an elevation of serum PSA should be considered as the possible coexistence of HPIN and prostatic carcinoma. There has been no consensus on the management of HPIN, but it is widely held that simple HPIN detected by extended needle biopsy has no therapeutic implications, but should be followed up at regular intervals. If there are changes in PSA and/or DRE, repeated needle biopsy is imperative. The natural biological behaviour of HPIN is yet poorly understood. Currently, most urological experts do not recommend antiandrogen therapy to patients with simple HPIN.
